Trinity Biotech Q4 2025 Earnings Report

Trinity Biotech EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.31
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Trinity Biotech Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $14.35 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Trinity Biotech Announcement Details

• Quarter: Q4 2025
• Date: 5/21/2026
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Trinity Biotech (NASDAQ:TRIB) is a global diagnostic healthcare company headquartered in Bray, Ireland. The firm specializes in the development, manufacture and marketing of in vitro diagnostic products aimed at the detection and management of chronic and infectious diseases. Its offerings are designed to deliver timely and accurate results for a range of healthcare settings, from central laboratories to point‐of‐care environments.

The company’s product portfolio includes a comprehensive array of assays and instrumentation. In the diabetes segment, Trinity Biotech provides hemoglobin A1c analyzers and glucose monitoring systems. It also offers serological and rapid tests for celiac disease, immunoassays for infectious diseases such as HIV and hepatitis B and C, and assays targeting cardiovascular risk markers. These products are used by hospitals, reference labs and clinics to support diagnosis, treatment monitoring and epidemiological surveillance.

Trinity Biotech serves a worldwide customer base through direct sales operations in North America and Europe, together with a network of distributors in Asia Pacific, Latin America and the Middle East. Its manufacturing sites operate under internationally recognized quality standards, ensuring regulatory compliance across multiple jurisdictions. The company’s global footprint and supply chain infrastructure enable it to respond to regional healthcare needs efficiently.

Supported by an experienced leadership team, Trinity Biotech maintains collaborations with research institutions and healthcare providers to drive innovation in diagnostic testing. Ongoing investment in product development and strategic partnerships underpins the company’s commitment to addressing emerging healthcare challenges and improving patient outcomes around the world.